What's in Bial - Portela C S.A.'s pipeline?

Bial - Portela C S.A. has 31 drugs in our index: 4 marketed, 0 filed, 1 in Phase 3, 8 in Phase 2, 18 in Phase 1.

Which companies overlap with Bial - Portela C S.A.'s portfolio?

Top competitors by shared drug class: Ain Shams University, Al-Azhar University, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Cinnagen.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bial-portela-c-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Bial - Portela C S.A. — Portfolio Competitive Intelligence Brief

Bial - Portela C S.A. pipeline: 4 marketed, 0 filed, 1 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 1 Phase 3 8 Phase 2 18 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
L-DOPA/DDCI	L-DOPA/DDCI	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopaminergic system	Neurology
ESL	ESL	marketed	Voltage-gated sodium channel blocker; anticonvulsant	Voltage-gated sodium channels (Nav)	Neurology
levodopa/dopa decarboxylase inhibitor	levodopa/dopa decarboxylase inhibitor	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (peripheral inhibition); dopamine receptors (central effect)	Neurology
Ongentys	Ongentys	marketed		Catechol O-methyltransferase, Catechol O-methyltransferase	Neuroscience
ESL - Part II	ESL - Part II	phase 3	Voltage-gated sodium channel inhibitor	Voltage-gated sodium channels (Nav)	Neurology

Therapeutic area mix

Neurology · 4
Diabetes · 1
Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Al-Azhar University · 1 shared drug class
AstraZeneca · 1 shared drug class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
Cinnagen · 1 shared drug class
Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
Dong-A ST Co., Ltd. · 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bial - Portela C S.A.:

Cite this brief

Drug Landscape (2026). Bial - Portela C S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bial-portela-c-s-a. Accessed 2026-05-16.